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Depression and the Usefulness of a
Disease Management Program in Heart Failure
Insights From the COACH (Coordinating study evaluating
Outcomes of Advising and Counseling in Heart failure) Study
Tiny Jaarsma, RN, PHD,* Ivonne Lesman-Leegte, RN, PHD,* Hans L. Hillege, MD, PHD,*‡
Nic J. Veeger, PHD,‡ Robbert Sanderman, PHD,† Dirk J. van Veldhuisen, MD, PHD,*
on behalf of the COACH Investigators
Groningen, the Netherlands
Objectives Our aim was to study the possible role of depressive symptoms in the effectiveness of a disease management
program (DMP) in heart failure (HF) patients.
Background Disease management programs are recommended in current HF guidelines, but certain patient groups, such as
those with depression, might be less responsive to such programs.
Methods From the data of a large multicenter study, in which we examined the effect of a DMP in HF patients, we investi-
gated a potential interaction between depressive symptoms at baseline and the effect of such a program.
Results Of the 958 HF patients (37% female; age 71  11 years; New York Heart Association functional class II to IV),
377 (39%) reported depressive symptoms at baseline. During 18 months of follow-up, the primary end point
(composite of all-cause mortality and HF readmission) occurred in 39% of the nondepressed patients and 42%
of depressed patients. In the overall sample, there was no significant effect of DMP on the composite primary
end point. The effect of the DMP was significantly different in nondepressed than in depressed HF patients. A
significant effect modification by depressive symptoms was observed in evaluating the effect of the DMP on all-cause
mortality and HF readmission (p  0.03). In patients without depressive symptoms, DMP resulted in a trend for lower
incidence of the primary end point (hazard ratio: 0.8, 95% confidence interval: 0.61 to 1.04), whereas the reverse was
observed in patients with depressive symptoms (hazard ratio: 1.3, 95% confidence interval: 0.95 to 1.98).
Conclusions Depressive symptoms in patients with HF have a major effect on the usefulness of DMP. Identification of depres-
sive symptoms before enrollment in a DMP might lead to more accurate use of a DMP, because depressive pa-
tients might not benefit from a general program. (Netherlands Heart Foundation Coordinating study evaluating
Outcomes of Advising and Counselling in Heart Failure; ISRCTN98675639) (J Am Coll Cardiol 2010;55:
1837–43) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.082p
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amplementation of disease management programs (DMPs)
or heart failure (HF) patients are a class I recommendation
n the current HF guidelines (1,2). Despite several studies
eporting on decreased readmission and mortality rates, it is
ot yet clear what the most optimal model of HF manage-
ent is. There are key features of successful DMPs;
owever, there still is a need for improvement of existing
rom the Departments of *Cardiology, †Health Psychology (RS), and ‡Epidemiol-
gy, University Medical Center Groningen, University of Groningen, Groningen, the
etherlands. The COACH study was supported by a program grant of the
etherlands Heart Foundation (2000Z003). Dr. van Veldhuisen is Clinical Estab-
ished Investigator of the Netherlands Heart Foundation (D97-017).c
Manuscript received September 7, 2009; revised manuscript received November 11,
009, accepted November 18, 2009.rograms and for defining an optimal approach for specific
atient groups (3–5).
Depression is a major problem in HF patients, and the
revalence of depressive symptoms in HF patients is signif-
cantly higher compared with an age- and sex-matched
opulation (6,7). Patients with depressive symptoms have
orse outcomes in terms of readmission rate and mor-
ality and are described as having considerably increased
ealth care costs (8,9). One would reason that the best
emedy to improve outcomes might be to cure the
epression. However, recent studies report only limited
ffects of psychotherapy and antidepressant medication
reatment on outcomes of depression in cardiac patients,
nd no intervention studies in depressive HF patients are
urrently known (10,11).
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Depression and HF April 27, 2010:1837–43Depressive symptoms are a
risk factor for nonadherence with
the HF regimen, such as medi-
cation, diet, and exercise. Non-
adherence in turn is known to be
related to increased readmission
and mortality (12–15). Improv-
ing adherence by increasing
knowledge and skills of patients is
the goal of DMPs. These pro-
grams assume an active role for
motivated patients and therefore
might be less suitable for depres-
sive patients. To study this possi-
ble role of depression in HF man-
agement, we analyzed patients
ith and without depressive symptoms enrolled in the
OACH (Coordinating study evaluating Outcomes of Ad-
ising and Counseling in Heart failure) study (16).
ethods
esign and intervention. The methods and primary re-
ults of the COACH study have been previously reported
16,17). The COACH study is a randomized controlled
rial investigating the effect of a DMP on readmission for
F and mortality. Patients were randomly assigned into 1
f the treatment strategies: 1) basic support; 2) intensive
upport; or 3) a control group. Patients assigned to the
ontrol group received routine management by the cardiol-
gist and general practitioner. No additional follow-up by
n HF nurse was provided. Basic support consisted of
atient education, additional visits to an HF nurse every 3
onths, and telephone access to an HF nurse during office
ours. Intensive support additionally included monthly
ontact with an HF nurse, multidisciplinary advice, home
isits, and 24-h access to an HF team during 18 months.
atients. Patients were included in the study during ad-
ission for HF (New York Heart Association [NYHA]
unctional class II to IV), with HF as the primary diagnosis
16). All patients had been admitted to the hospital with
F symptoms and were classified as NYHA functional class
I to IV. The diagnosis was made on the basis of a
ombination of typical signs and symptoms for which
ospital stay was considered necessary, including the need
or intravenously administered medication. Patients were 18
ears or older and had evidence of structural underlying
eart disease as shown at cardiovascular imaging. Both
atients with impaired left ventricular ejection fraction
LVEF) and those with preserved LVEF could participate.
easons for exclusion were: concurrent inclusion in a study
equiring additional visits to research health care personnel;
estrictions that make the patient unable to fill in data
ollection forms; invasive intervention within the last 6
onths (percutaneous transluminal coronary angioplasty,
Abbreviations
and Acronyms
CES-D  Center for
Epidemiological Studies
Depression Scale
CI  confidence interval
DMP  disease
management program
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationoronary artery bypass graft, heart transplantation, valve teplacement) or planned during the following 3 months; or
ngoing evaluation for heart transplantation. The study
omplied with the Declaration of Helsinki, and a central
ppointed ethics committee approved the research protocol.
nformed consent was obtained from the subjects.
ata collection. DEPRESSIVE SYMPTOMS. Data on depres-
ive symptoms were collected with the Center for Epide-
iological Studies Depression Scale (CES-D). This is a
alid instrument that has been established in cardiac and
oncardiac patients (18) to identify high-risk patients and
tudy the relationships between depressive symptoms and other
ariables. A total sum score is calculated (0 to 60), with higher
cores indicating more depressive symptoms. A cutoff point of
6, which is generally used to define patients at risk for
linical depression, was used to distinguish between HF
atients with depressive symptoms (CES-D 16) and
atients without depressive symptoms (CES-D 16).
Data were collected during hospital stay shortly before dis-
harge from the hospital when patients were clinically stable.
ND POINTS. Primary end points were time-to-death or
eadmission for HF and the number of days lost to death or
eadmission (unfavorable days). Major secondary end points
ere mortality and readmission. Data regarding readmission
nd mortality were collected and adjudicated by an inde-
endent end point committee.
EMOGRAPHIC AND CLINICAL DATA. Data were collected
rom patient chart and interview.
tatistical analysis. Baseline characteristics of patients with
epressive symptoms (CES-D 16) and without depressive
ymptoms (CES-D 16) in the control and intervention
roups were summarized by mean (SD) for continuous vari-
bles and by frequency for categorical variables. Kaplan-Meier
urves were constructed for the different time-to-event evalu-
tions. To estimate effect sizes, hazard ratios (HRs) with 95%
onfidence intervals (CIs) were calculated with multivariable
ox proportional hazards regression models. In these analyses,
ffect modification of intervention by the presence of depres-
ive symptoms was specifically considered by including inter-
ction terms in the models. Because no differences were found
etween patients in either intervention group (basic and
ntensive), data were pooled for the 2 intervention groups and
ompared with the control group. Because the proportion of
omen and patient NYHA functional classification in the
ontrol and intervention groups was significantly different
etween the patients with and without depressive symptoms,
e adjusted for NYHA functional classification and sex in all
ox regression analyses. A p value of 0.05 was taken as the
evel of significance. Differences regarding the unfavorable days
nd number of readmissions were analyzed with chi-square
nd Mann-Whitney tests.
The funding source (the Netherlands Heart Foundation)
id not have any role in collecting, analyzing, or interpreting
he data or in writing or submitting the report.
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tudy sample. Of the 1,023 included patients, data on
epressive symptoms at baseline were available in 958
atients (Fig. 1). The mean age of the patients was 71  11
ears, and 63% were men (Table 1). At admission most
atients were classified as NYHA functional class III or IV,
nd at discharge 51% were NYHA class II and 49% were
YHA class III or IV. Both patients with systolic HF and
ith a preserved LVEF were included; the mean LVEF was
4  15%, and 43% of the patients had HF with ischemic
tiology. At discharge, 96% of the patients were prescribed
diuretic, 83% were prescribed an angiotensin-converting
nzyme inhibitor or angiotensin receptor blocker, and 66%
ere prescribed a beta-blocker.
Of the total sample of 958 patients, 377 patients (39%)
eported depressive symptoms at baseline (CES-D 16).
f the depressed patients, 11% used antidepressive medi-
ation. Depressed patients were more often female and had
higher NYHA functional classification at discharge. No
ifferences were found between depressed and nondepressed
atients in other variables, such as age, LVEF, or HF
edication.
nteraction between outcome and depressive symptoms.
RIMARY END POINT: HF HOSPITALIZATION OR DEATH.
e found a statistically significant effect modification by
epressive symptoms in the effect of the DMP on the primary
nd point—HF readmission and all-cause mortality—that is,
here was a difference in the effect of the intervention in
Figure 1 Flow of Participants
Enrollment and follow-up of the patients in the trial (consort diagram). Patient data
(basic support and intensive support) were pooled into 1 group. CES-D  Center fepressed and nondepressed patients; uncorrected, p  0.05; norrected for NYHA functional class and sex, p  0.03.
azard ratios are presented for the depressed and nonde-
ressed patients separately.
ondepressed patients. A total of 39% of the 581 nonde-
ressed patients were hospitalized for HF or died within the
8 months of the study. Patients in the DMP reached their
rimary end point less often (36%) than patients in the
ontrol group (44%), although this effect did not reach
tatistical significance (HR: 0.8; 95% CI: 0.60 to 1.03, p 
.08). After correction for NYHA functional classification
nd sex, the HR remained 0.8 (95% CI: 0.61 to 1.04, p 
.11) (Fig. 2).
epressed patients. Of the 377 depressed patients, a total of
1% were hospitalized for HF or died within the 18 months
f the study. In contrast to the nondepressed patients,
epressed patients did not benefit from the DMP. Patients
n the DMP more often reached the primary end point
46%) compared with patients in the control group (37%)
ith an HR of 1.5 (95% CI: 1.04 to 2.15, p  0.03). After
djusting for NYHA functional classification and sex, this
ffect lost statistical significance with an HR of 1.3 (95% CI:
.95 to 1.98, p  0.12).
RIMARY END POINT: UNFAVORABLE DAYS. Patients with-
ut depressive symptoms had fewer unfavorable days com-
ared with patients with depressive symptoms (median of 8
ays vs. 11 days, p  0.059). Nondepressed patients in the
MP group had significantly fewer unfavorable days than
2 intervention groups
emiological Studies Depression Scale.in the
or Epidondepressed patients in the control group (median of 7
d
p
c
t
S
M
2
d
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Depression and HF April 27, 2010:1837–43ays vs. 15 days, p  0.029). The reverse was found in
atients with depressive symptoms where patients in the
ontrol group had fewer unfavorable days than patients in
he DMP group (median 2 vs. 18 days, p  0.001).
Baseline Characteristics According to Group AsTable 1 Baseline Characteristics According
All
(n  958) (n
Demographic variables
Age, yrs 71 11 7
Female sex 37%
Clinical variables
LVEF, % 34 15 3
History of AF 36%
NYHA (at discharge)
II 51%
III–IV 49%
Ischemic etiology 43%
1 comorbidity 79%
Prior HF admission 67%
Medication at discharge
ACE/ARB 83%
Diuretics 96%
Beta-blockers 66%
Lipid-lowering drugs 38%
Antidepressants 7%
Depression
CES-D total score 15 11
Values are mean  SD or %. *p  0.05.
ACE/ARB  angiotensin-converting enzyme inhibitor/angiotensin r
Studies Depression Scale; HF  heart failure; LVEF  left ventricular
Figure 2 Interactions Between Depression and Intervention and
Interactions (p values) between the presence of depression and the effect of the i
dence intervals (CIs) for the patients with depressive symptoms (n  377) and no
functional class and sex. HF  heart failure.EPARATE COMPONENTS OF THE PRIMARY END POINT:
ORTALITY AND HF READMISSION: MORTALITY. A total of
6% of the nondepressed and 29% of the depressed patients
ied within the study period of 18 months. A significant effect
ent and Depressive Symptomsroup Assignment and Depressive Symptoms
pressive Symptoms
(n  581)
Depressive Symptoms
(n  377)
l
1)
Intervention
(n  380)
Control
(n  116)
Intervention
(n  261)
1 70 12 69 12 70 12
32% 51% 40%*
4 33 14 36 15 34 16
35% 35% 39%
55% 51% 41%*
45% 49% 59%
44% 32% 44%
76% 84% 81%
71% 66% 66%
83% 83% 83%
96% 97% 95%
65% 66% 67%
39% 34% 36%
3% 10% 12%
8 4 27 9 26 8
blocker; AF  atrial fibrillation; CES-D  Center for Epidemiological
fraction; NYHA New York Heart Association functional class.
ard Ratios for Depressed and Nondepressed Patients
ntion (disease management program [DMP]), hazard ratios and the 95% confi-
ssive symptoms (n  581) separately, corrected for New York Heart Associationsignmto G
No De
Contro
 20
3 1
34%
3 1
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April 27, 2010:1837–43 Depression and HFodification of group assignment by depressive symptoms was
ound for mortality (uncorrected p  0.002, corrected for
YHA functional class, p  0.007).
Nondepressed patients in the DMP had significantly
ower mortality (22%) compared with patients in the control
roup (32%) (HR: 0.7, 95% CI: 0.49 to 0.93, p 0.02) and
fter correction for NYHA functional class and sex (HR:
.7, 95% CI: 0.49 to 0.94, p  0.02) (Fig. 2).
Depressed patients in the DMP had a higher mortality
ate (32%) versus depressed patients in the control group
21%) (HR: 1.6, 95% CI: 1.09 to 2.46, p  0.04). After
orrection for NYHA functional class and sex, this effect
ost statistical significance (HR: 1.5, 95% CI: 0.94 to 2.39,
 0.11).
EPARATE COMPONENTS OF THE PRIMARY ENDPOINT: HF
EADMISSION. A total of 26% of the nondepressed and
8% of the depressed patients had an HF readmission.
here was no significant effect modification of group
ssignment by depressive symptoms HF readmission (p 
.27) (Fig. 2).
LL-CAUSE READMISSION. Overall, in patients without de-
ressive symptoms the DMP led to lower readmission rates;
n patients with depressive symptoms the reverse was found
Table 2). The relationship of all-cause readmission and the
MP was modified significantly by depressive symptoms
p value for interaction  0.02). Also after correction for
YHA functional class and sex, depressive patients in the
MP had significantly higher readmission rates compared
ith depressed patients in the control group (HR: 1.47,
5% CI: 1.08 to 1.99, p  0.01). In the nondepressed
atients, patients in the DMP had slightly fewer readmis-
ions than patients in the control group (Table 2); however,
his was not statistically significant (HR: 0.89, 95% CI: 0.70
o 1.12, p  0.32).
iscussion
he main finding of the present study is that depressive
ymptoms have an impact on effectiveness of DMP in HF
atients. Specifically, in patients without depressive symp-
oms the DMP significantly decreased the number of days
ost to death or readmission and reduced mortality rates. In
ontrast to these findings, we found that in patients with
epressive symptoms the DMP did not lead to an expected
eadmission Rates According to Group Assignment and DepressiveTable 2 Readmission Rates According to Group Assignment an
All
(n  958)
No Depressive Sy
All
(n  581)
Con
(n 
All-cause readmission 56% 53% 5
CV (including HF) readmission 43% 41% 4
HF readmission 26% 24% 2
Non-CV readmission 27% 24% 2Control versus intervention in patients with depressive symptoms; †p  0.01; ‡p  0.05.
CV  cardiovascular; HF  heart failure.eduction in readmissions but led to an increase in readmis-
ions. Additionally, depressed patients did not have a mortality
enefit from the DMP.
These data shed new light on the importance of tailoring
nterventions to individual patients and can be used to
mprove DMPs. Patients with depressive symptoms should
robably not be included in a general HF management
rogram that is not specifically targeted at managing de-
ressive symptoms and their consequences.
The primary objective of the COACH study was to test
hether a DMP consisting of education and support by a
urse could lead to reduced HF readmission and mortality.
nclusion criteria were liberal, and patients are representa-
ive of patients in daily practice. Patients with overt psychi-
tric disorders were excluded, but a high percentage of
atients (39%) were found to have depressive symptoms,
dentified by a validated questionnaire. The intervention in
he COACH study mainly focused on adherence to lifestyle
hanges, symptom recognition by patients, and consultation
ith a health care professional for changes in symptoms.
lthough psychosocial issues of patients were addressed
n the training of the nurses, and worries and feelings of
atients were assessed and discussed, no specifically tailored
ntervention was available for patients with depressive symp-
oms. This is in line with most DMPs that offer similar
nterventions to depressed and nondepressed patients and that
o not specifically address comorbid (mental) illnesses (19).
Depression—with its associated lack of motivation, help-
essness, and lack of energy—is known to obstruct active
articipation in lifestyle changes and symptom recognition
eeded for taking appropriate action in case of worsening
ymptoms (20). The goals of the intervention were appar-
ntly realistic and obtainable for nondepressed patients but
ot for depressed patients in whom it might have had a
eleterious effect when compared with a less intrusive
reatment regimen (standard care). One can imagine that
epressed patients are less amendable or responsive to an
ntervention. They might have felt confronted with the
isease and with their limitations by the attention drawn to
t by the health care professionals in the DMP. Patients
ight well have somaticized more, and the increased
wareness of symptoms by both patients and health care
roviders in the DMP combined with the difficulty of
orrectly interpreting and treating symptoms of depressed
ptomspressive Symptoms
s (n  581) Depressive Symptoms (n  377)
Intervention
(n  380)
All
(n  377)
Control
(n  116)
Intervention
(n  261)
52% 60% 50%*† 64%*†
39% 45% 38%*‡ 48%*‡
23% 28% 24% 30%
24% 30% 26% 32%Symd De
mptom
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6%
5%
5%
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Depression and HF April 27, 2010:1837–43F patients could have resulted in an increased readmission
ate. Depressive patients probably feel more demoralized,
iven their health status, and for them it is probably more
ifficult to take advantage of the intervention compared
ith nondepressed patients, who also have decreased health
tatus but might be more capable and motivated to take
dvantage of the advice of the nurse.
Although these are mere hypothetical explanations, sim-
lar findings have been reported in a study in myocardial
nfarction (MI) patients by Frasure-Smith et al. (21), who
ound that a nurse-led intervention in MI patients had a
armful impact on depressed women. They also report that
ncreased contact with a nurse might have reminded pa-
ients of their MI and increased distress.
These results raise the issue of how to optimally manage
hese complex patients that suffer from both physical and
sychological symptoms. That psychosocial problems are
nderestimated and undertreated in HF patients (22,23)
as confirmed by the present finding that only 10% to 12%
f the patients with depressive symptoms were prescribed
ntidepressant medication. Although we did not assess a
linical diagnosis of depression but rather the presence of
epressive symptoms, the CES-D is a well-validated scale
hat does identity patients who are at high risk of developing
depressive disorder. Earlier studies have shown that, even
n HF patients with a clinical diagnosis of depression, only
7% to 33% received antidepressant medication (24). De-
ressive symptoms need to be recognized during enrollment
n a DMP. For these patients a standard DMP should not
e applied, and a tailored intervention addressing both
sychological and HF aspects is probably more suitable.
his implies that a multidisciplinary approach is needed to
ombine issues specifically related to HF and more psycho-
ogical problems, focusing on HF-specific lifestyle changes
nd optimization of HF medication, antidepressants, and
ounseling (25).
Nondepressed patients in this study seemed to benefit
rom the intervention by lower primary end point. The
ntervention in the study assumed an active role for patients by
ducation on symptom recognition and lifestyle changes,
hich is known to decrease mortality and readmission (26,27).
tudy limitations. This present study has a few potential
imitations. Because the analyses are subgroup analysis and
his study was not designed to prospectively follow de-
ressed and nondepressed patients, the results should be
nterpreted with caution. Secondly, although used in
revious publications (17,28), the rather novel end point
f “unfavorable days” might be challenging to interpret.
evertheless, we believe the presented data can generate
ew hypotheses and shed new light on the implementa-
ion of DMPs in HF patients.
onclusions
his study showed that depressive symptoms in patients
ith HF have a major effect on the usefulness of DMPs.
1ondepressed HF patients can benefit from a DMP mainly
ocusing on education and counseling, whereas patients
ith depressive symptoms do not benefit in terms of
ortality or readmission. A more specific approach for
epressed patients is needed in which a conjoint therapy of
F management and psychological problems could be
uccessful and in which special attention is given to adher-
nce and psychopharmacology.
eprint requests and correspondence: Dr. Tiny Jaarsma, De-
artment of Cardiology, University Medical Centre Groningen,
niversity of Groningen, PO Box 30.001, 9700 RB Groningen,
he Netherlands. E-mail: t.jaarsma@thorax.umcg.nl.
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